Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2013: Faldaprevir Triple Therapy Effective Across Patient Subgroups
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 27 November 2013 00:00
- Written by Michael Carter
The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir in combination with pegylated interferon and ribavirin was effective across a range of subgroups of patients with genotype 1 infection -- including prior relapsers and non-responders -- in the STARTVerso clinical trials program, according to research presented at the recent AASLD Liver Meeting in Washington, DC.
FDA Approves Simeprevir (Olysio) for Chronic Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 26 November 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration last Friday approved Janssen/Medivir's next-generation hepatitis C virus (HCV) protease inhibitor simeprevir -- to be marketed under the brand name Olysio -- as an add-on to interferon-based therapy for the treatment of people with genotype 1 chronic hepatitis C. It is not yet approved for use in interferon-free combinations.
AbbVie All-Oral Regimen Produces 96% Cure Rate, Effective Against Both HCV 1a and 1b
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by AbbVie
A 12-week interferon-free quadruple regimen of 3 direct-acting antiviral agents plus ribavirin led to sustained virological response in 95% of previously untreated, non-cirrhotic hepatitis C patients with harder-to-treat HCV subtype 1a and 98% of those with subtype 1b, AbbVie announced this week.
AASLD 2013: Faldaprevir All-oral Regimen Shows 100% Early Sustained Response for HCV 1a
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of faldaprevir, deleobuvir, and PPI-668 led to 4-week post-treatment sustained virological response (SVR4) in all treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing Phase 2 trial, according to a late-breaking poster presentation at the 64th AASLD Liver Meeting this month in Washington, DC.
AASLD 2013: Black Hepatitis C Patients Do Well on Sofosbuvir Oral Regimens
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
Interferon-free treatment using a single daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent anti-HCV activity and was generally well-tolerated in a primarily African-American inner city population with genotype 1a hepatitis C, researchers reported at the recent AASLD Liver Meeting in Washington, DC. Adding a third drug resulted in high early post-treatment response rates with shorter treatment.
More Articles...
- AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C
- AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients
- AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study
- AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
Web Design and Development by